#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Asthma Dermatitis atopic Breast cancer metastatic Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Ichthyosis Extra-osseous Ewing's sarcoma Hypotransferrinaemia Hereditary haemorrhagic telangiectasia Chondrodystrophy Immune-mediated myasthenia gravis Narcolepsy Glioblastoma Leiomyosarcoma Phaeochromocytoma Acute graft versus host disease Iron overload Fibrous dysplasia of bone Mastocytosis Burkitt's lymphoma More trials…

    Learn about Rare Diseases

    Wolfram syndrome Wolfram syndrome – Treatment Focal segmental glomerulosclerosis – Basic Information SAPHO syndrome – Treatment Turner’s syndrome – Diagnostics Factor IX deficiency – Life with Disease Niemann-Pick disease – Trials in Disease Choroid melanoma – Basic Information Osteosarcoma recurrent – Treatment Progressive supranuclear palsy – Basic Information More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Jab-21822 Cefixime Trihydrate IDROXIOLEIC ACID Piritramide Capecitabine Odm-111 Barium Sulfate L-Histidine Emtricitabine Tiragolumab Ace Inhibitors, Plain IADADEMSTAT Ht-29-A Human Mesenchymal Stem Cells Eptinezumab Garadacimab Safinamide Ciprofloxacin Hydrochloride Crovalimab Ptg-Carcik-Cd19 More therapies…

    Learn about Your Condition

    Laryngeal cancer stage III Thrombosis Desmoid tumour Axial spondyloarthritis Chronic lymphocytic leukaemia Renal impairment Leukoencephalopathy Nephrotic syndrome Acute kidney injury Vulval cancer recurrent Demyelination Anxiety disorder Lymphangioleiomyomatosis Bipolar I disorder Vitamin D deficiency More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. University Of Debrecen

University Of Debrecen

Mpuotv Ziwpquql Kvttw 2em Dccfnxekp 4iezv Hcnqjyp

Want to learn more about this study or check if you can participate? Contact us.

  • Study on Bomedemstat for Patients with Essential Thrombocythemia Not Responding to or Intolerant of Hydroxyurea, Comparing with a Drug Combination

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Anagrelide Hydrochloride Monohydrate
    • Bomedemstat
    • Peginterferon Alfa-2A
    Belgium France Germany Hungary Italy The Netherlands +4

  • Study on the Effectiveness of Povorcitinib for Adults with Nonsegmental Vitiligo

    Not recruiting

    3 1
    Investigated Diseases:
    • Vitiligo
    Investigated Drugs:
    • Povorcitinib
    Bulgaria France Germany Hungary Italy Poland

  • Study on the Long-term Safety of Vedolizumab for Children with Ulcerative Colitis or Crohn’s Disease

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Colitis ulcerative
    • Crohn’s disease
    Investigated Drugs:
    • Vedolizumab
    Hungary Poland

  • Study of Niraparib, Abiraterone Acetate, and Prednisone for Patients with Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Abiraterone
    • Abiraterone Acetate
    • Degarelix
    Belgium Bulgaria Czechia Denmark France Germany +7

  • Study on Long-Term Safety and Efficacy of Deucravacitinib for Patients with Moderate-to-Severe Plaque Psoriasis

    Not recruiting

    3 1
    Investigated Drugs:
    • Deucravacitinib
    Czechia Finland France Germany Hungary Poland +2

  • Study of Evolocumab to Prevent Heart Disease Events in High-Risk Patients Without Previous Heart Attack or Stroke

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Evolocumab
    Austria Belgium Bulgaria Czechia Denmark Estonia +16

  • Study on the Safety and Effectiveness of Epcoritamab with R-CHOP for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Epcoritamab
    • Cyclophosphamide
    • Doxorubicin Hydrochloride
    Austria Belgium Bulgaria Croatia Czechia Denmark +10

  • Study on the Safety and Effectiveness of Epcoritamab with Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular Lymphoma

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Follicle centre lymphoma follicular grade I II – III refractory
    Investigated Drugs:
    • Epcoritamab
    • Lenalidomide
    • Rituximab
    Austria Belgium Czechia Denmark France Germany +8

  • Study Comparing Elranatamab and Lenalidomide for Patients with Newly Diagnosed Multiple Myeloma After Stem-Cell Transplantation

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma
    Investigated Drugs:
    • Elranatamab
    • Human Normal Immunoglobulin
    • Lenalidomide
    Austria Belgium Czechia Finland France Germany +8

  • Study on the Effects of Rusfertide (PTG-300) for Patients with Polycythemia Vera

    Not recruiting

    3 1
    Investigated Diseases:
    • Polycythaemia vera
    Investigated Drugs:
    • Rusfertide
    Austria Belgium Czechia France Germany Hungary +5
Previous Page
1 … 35 36 37 38 39 … 52
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!